Treatment of Advanced Human Immunodeficiency Virus Type 1 Disease with the Viral Entry Inhibitor PRO 542

Viral entry inhibitors represent an emerging mode of therapy for human immunodeficiency virus type 1 (HIV-1) infection. PRO 542 (CD4-immunoglobulin G2) is a tetravalent CD4-immunoglobulin fusion protein that broadly neutralizes primary HIV-1 isolates. PRO 542 binds to the viral surface glycoprotein...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Jacobson, Jeffrey M., Israel, Robert J., Lowy, Israel, Ostrow, Nancy A., Vassilatos, Linda S., Barish, Melanie, Tran, Diep N. H., Sullivan, Brian M., Ketas, Thomas J., O'Neill, Tobias J., Nagashima, Kirsten A., Huang, Wei, Petropoulos, Christos J., Moore, John P., Maddon, Paul J., Olson, William C.
Formato: Artigo
Idioma:Inglês
Publicado: American Society for Microbiology 2004
Assuntos:
Antiviral Agents
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC321533/
https://ncbi.nlm.nih.gov/pubmed/14742190
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.48.2.423-429.2004
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares